New Delhi: The feud over Ranbaxy founder Bhai Mohan Singh's will is headed for a pitched legal battle with his youngest son and Max Healthcare Chairman Analjit Singh, the biggest beneficiary of the will, going ahead to move court to file for probate (official proving) this week.
Mohan Singh’s eldest son Parvinder Singh’s children - Malvinder and Shivender, the current owners of Ranbaxy and Fortis Hospital, have already challenged the move.
"We will file for probate in the court sometime in this week but have not decided as to which court will we move but largely it has to be in a lower court," A K Sharma, counsel of Analjit Singh and also one of the executors of the will, told PTI.
Sharma said Malvinder and Shivender are opposing the move. "They have filed a caveat against executing the will and have already issued notice against the executers," he said.
He, however, said a settlement through dialogue was still an option. "We are interested to settle the issue through dialogue but will not make a first move," he added.
Sharma said despite the willingness to settle the issue, Analjit has decided to move court to file for probate of the will.
The will could only be authenticated after notices were issued to other parties and they will have 30 days period to respond, Sharma said.
The dispute is mainly on account of about 24 lakh disputed shares of Ranbaxy, which are claimed to have been held by Bhai Mohan Singh directly or indirectly through trusts and investment companies.
Sharma said Analjit had to fight the case as he, according to the will, had been made the heir to the litigation.
The will had directed Analjit to sell the disputed shares subject to a favourable ruling from court and transfer the proceeds to the Bhai Mohan Singh Foundation.
These shares are estimated to be valued at around Rs 125 crore at the current market price.
Comments
0 comment